Celyad Oncology SA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.celyad.com
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeMultiple Myeloma
- Interventions
- Biological: CM-CS1 T-cell infusion
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Celyad Oncology SA
- Target Recruit Count
- 12
- Registration Number
- NCT02203825
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.
Phase 3
Completed
- Conditions
- Heart Failure
- Interventions
- Biological: Injection of C3BS-CQR-1Biological: Sham, no injection
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Celyad Oncology SA
- Target Recruit Count
- 315
- Registration Number
- NCT01768702
- Locations
- 🇧🇪
Centre Hospitalier Universitaire de Liège, Liège, Belgium
🇮🇱Western Galilee Hospital, Nahariya, Israel
🇵🇱Biegański Hospital, Łódź, Poland
C-Cure Clinical Trial
Phase 2
Completed
- Conditions
- Heart Failure Class II or III
- Interventions
- Biological: C-Cure
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2012-09-05
- Lead Sponsor
- Celyad Oncology SA
- Target Recruit Count
- 240
- Registration Number
- NCT00810238
- Locations
- 🇧🇪
CardioVascular Center, Aalst, Belgium
🇧🇪Virga Jesse Ziekenhuis, Hasselt, Belgium
🇧🇪Centre Hospitalier Universitaire, Liège, Belgium
© Copyright 2025. All Rights Reserved by MedPath